On the contrary, in the study by Que et al. (2019), which included 89 NSCLC patients, EpCAM+/EGFR+/CK+/CD45− CTC counts were shown to be statistically lower in late-stage patients (mean number 14.6) compared to that in early stage ones (mean number 49.5) [34]. The gene discussed is EPCAM; the disease is non-small cell lung carcinoma.